Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats.

Steeb CB, Trahair JF, Tomas FM, Read LC

The American journal of physiology1 Jun 1994Cited by 65 (Europe PMC)

PMID7912894DOI10.1152/ajpgi.1994.266.6.g1090PepBankPUB-07912894

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, IGF-I and LR3IGF-I each induced a dose-dependent increase in gastrointestinal tissue weight.
In plain wordsIn rats, the LR3 IGF-I analogue, like IGF-I, increased the weight of gut tissue in a dose-dependent way.
Peptide
IGF-1 LR3
Outcome
IncreaseGastrointestinal tissue weight
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Both peptides induced a dose-dependent increase in gastrointestinal tissue weight.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289401
02AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, 278 micrograms/day LR3IGF-I increased total gut weight by 43%.
In plain wordsIn rats, the highest dose of the LR3 IGF-I analogue increased total gut weight.
Peptide
IGF-1 LR3
Outcome
IncreaseTotal gut weight
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Measurements
total gut weight increase
43%
278 micrograms/day LR3IGF-I
Source sentences
Summary
Total gut weight, small intestinal weight, and small intestinal length increased by 43, 47, and 13%, respectively, after treatment with 278 micrograms/day of LR3IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289402
03AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, 278 micrograms/day LR3IGF-I increased small intestinal weight by 47%.
In plain wordsIn rats, the highest dose of the LR3 IGF-I analogue increased small intestine weight.
Peptide
IGF-1 LR3
Outcome
IncreaseSmall intestinal weight
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Measurements
small intestinal weight increase
47%
278 micrograms/day LR3IGF-I
Source sentences
Summary
Total gut weight, small intestinal weight, and small intestinal length increased by 43, 47, and 13%, respectively, after treatment with 278 micrograms/day of LR3IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289403
04AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, 278 micrograms/day LR3IGF-I increased small intestinal length by 13%.
In plain wordsIn rats, the highest dose of the LR3 IGF-I analogue made the small intestine longer.
Peptide
IGF-1 LR3
Outcome
IncreaseSmall intestinal length
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Measurements
small intestinal length increase
13%
278 micrograms/day LR3IGF-I
Source sentences
Summary
Total gut weight, small intestinal weight, and small intestinal length increased by 43, 47, and 13%, respectively, after treatment with 278 micrograms/day of LR3IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289404
05AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, peptide treatment (IGF-I or LR3IGF-I) increased crypt depth.
In plain wordsIn rats, treatment with IGF-I or the LR3 IGF-I analogue made the gut crypts deeper.
Peptide
IGF-1 LR3
Outcome
IncreaseCrypt depth
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Crypt depth and villus height increased after peptide treatment
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289405
06AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, peptide treatment (IGF-I or LR3IGF-I) increased villus height.
In plain wordsIn rats, treatment with IGF-I or the LR3 IGF-I analogue made the gut villi taller.
Peptide
IGF-1 LR3
Outcome
IncreaseVillus height
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Crypt depth and villus height increased after peptide treatment
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289406
07AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, peptide treatment increased the crypt cell population by 33%.
In plain wordsIn rats, IGF-I or the LR3 IGF-I analogue increased the number of cells in the gut crypts.
Peptide
IGF-1 LR3
Outcome
IncreaseCrypt cell population
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Measurements
crypt cell population increase
33%
peptide treatment
Source sentences
Summary
with an associated increased crypt cell population (+33%), cells per villus column (+34%), and villus cell density (+20%).
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289407
08AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, peptide treatment increased cells per villus column by 34%.
In plain wordsIn rats, IGF-I or the LR3 IGF-I analogue increased the number of cells in each villus column.
Peptide
IGF-1 LR3
Outcome
IncreaseCells per villus column
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Measurements
cells per villus column increase
34%
peptide treatment
Source sentences
Summary
with an associated increased crypt cell population (+33%), cells per villus column (+34%), and villus cell density (+20%).
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289408
09AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, peptide treatment increased villus cell density by 20%.
In plain wordsIn rats, IGF-I or the LR3 IGF-I analogue increased how densely cells packed in the gut villi.
Peptide
IGF-1 LR3
Outcome
IncreaseVillus cell density
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Measurements
villus cell density increase
20%
peptide treatment
Source sentences
Summary
with an associated increased crypt cell population (+33%), cells per villus column (+34%), and villus cell density (+20%).
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289409
10AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, peptide treatment produced proportional increments in proliferating cell nuclear antigen labeling.
In plain wordsIn rats, IGF-I or the LR3 IGF-I analogue increased a marker of cell division in the gut.
Peptide
IGF-1 LR3
Outcome
IncreaseProliferating cell nuclear antigen labeling
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Proportional increments in proliferating cell nuclear antigen labeling
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289410
11AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, peptide treatment left the crypt growth fraction unaltered.
In plain wordsIn rats, IGF-I or the LR3 IGF-I analogue did not change the crypt growth fraction.
Peptide
IGF-1 LR3
Outcome
No significant changeCrypt growth fraction
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Proportional increments in proliferating cell nuclear antigen labeling and an unaltered crypt growth fraction indicated that the balance between the proliferative and maturation compartment of the crypt was maintained.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289411
12AnimalAnimal study (in vivo)Efficacy outcome
In normal female rats, LR3IGF-I significantly reduced fecal nitrogen excretion.
In plain wordsIn rats, the LR3 IGF-I analogue reduced nitrogen lost in feces.
Peptide
IGF-1 LR3
Outcome
DecreaseFecal nitrogen excretion
Study
ratn: not reported in source
normal female rats
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
44, 111 or 278 micrograms/day · osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Fecal nitrogen excretion was significantly reduced in rats treated with LR3IGF-I
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of insulin-like growth factor (IGF) peptide infusion on the gastrointestinal tract, female rats (115 g, 6/group) were treated for 14 days with IGF-I or long R (LR3IGF-I; 0, 44, 111, or 278 micrograms/day) delivered by osmotic minipumps.
Report a problemFND-0791289412

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.